In hepatocellular carcinoma models, suppression of the p62–KEAP1–NRF2 pathway markedly enhances the efficacy of ferroptosis inducers such as Erastin and sorafenib [49]. This evidence concerns the gene KEAP1 and hepatocellular carcinoma.